Summary
The submitted claims predominantly concern hyperglycemia/diabetes risk and metabolic effects, but the provided FDA label excerpt only contains boxed-warning-related information about increased mortality in elderly patients with dementia-related psychosis and suicidality in adolescents/young adults. These diabetes/hyperglycemia-related claims are therefore unsupported by the supplied prescribing information and include multiple specific quantitative/statistical assertions that cannot be verified from the provided label.
Category Scores
Accurate Statements
Elderly patients with dementia-related psychosis treated with SEROQUEL (quetiapine) are at increased risk of death; and SEROQUEL is not approved for dementia-related psychosis.
Sections 5.1 and 17: increased risk of death and explicit statement that SEROQUEL is not approved for dementia-related psychosis.
Unsupported Statements
Seroquel (quetiapine) is linked to new-onset diabetes in some patients.
No diabetes/hyperglycemia/diabetes incidence information is present in the supplied prescribing information excerpt.
Seroquel (quetiapine) can worsen blood sugar control in some patients.
Not supported by the provided label excerpt.
FDA black-box warnings for Seroquel and similar drugs highlight the risk of hyperglycemia.
The supplied label excerpt’s boxed-warning topics concern increased mortality in elderly patients with dementia-related psychosis and suicidal thoughts/behaviors; it does not mention hyperglycemia.
Hyperglycemia associated with Seroquel can lead to diabetic ketoacidosis.
Not supported by the provided label excerpt.
Hyperglycemia associated with Seroquel can lead to type 2 diabetes.
Not supported by the provided label excerpt.
The risk of hyperglycemia, diabetic ketoacidosis, or type 2 diabetes is especially early in treatment with Seroquel.
Not supported by the provided label excerpt.
Incidence rates of diabetes in patients on quetiapine are reported as 1–5%.
Not supported by the provided label excerpt.
Diabetes incidence on quetiapine is higher than placebo (reported as 0.4–1.8%).
Not supported by the provided label excerpt.
Seroquel disrupts glucose metabolism.
Not supported by the provided label excerpt.
Seroquel blocks serotonin and histamine receptors, which promotes insulin resistance and weight gain.
Not supported by the provided label excerpt.
Insulin resistance and weight gain are key precursors to diabetes.
Not supported by the provided label excerpt.
Average weight gain with Seroquel is 4–10 pounds in the first year.
Not supported by the provided label excerpt.
Weight gain with Seroquel correlates with elevated fasting glucose and HbA1c levels.
Not supported by the provided label excerpt.
Genetic variants in the melanocortin-4 receptor amplify diabetes risk in vulnerable patients taking Seroquel.
Not supported by the provided label excerpt.
Patients with obesity have higher odds of diabetes risk with Seroquel.
Not supported by the provided label excerpt.
Patients with a family history of diabetes have higher odds of diabetes risk with Seroquel.
Not supported by the provided label excerpt.
Older age is associated with higher odds of diabetes risk with Seroquel.
Not supported by the provided label excerpt.
Native American, Black, and Hispanic ethnicity are associated with higher odds of diabetes risk with Seroquel.
Not supported by the provided label excerpt.
Children and adolescents on Seroquel have up to 3 times greater hyperglycemia risk than adults.
Not supported by the provided label excerpt.
Pre-existing metabolic issues increase risk of hyperglycemia with Seroquel.
Not supported by the provided label excerpt.
Concurrent use with other antipsychotics compounds the risk of hyperglycemia with Seroquel.
Not supported by the provided label excerpt.
Baseline and periodic fasting glucose and HbA1c testing are standard before and during Seroquel treatment (per APA guidelines).
Not supported by the provided label excerpt (and no APA guideline content is included).
Per APA guidelines, if fasting glucose exceeds 126 mg/dL or random glucose exceeds 200 mg/dL during Seroquel treatment, switching drugs or adding metformin is advised.
Not supported by the provided label excerpt (and no APA guideline content is included).
Weight monitoring every 3 months helps catch issues early during Seroquel treatment.
Not supported by the provided label excerpt.
In the CATIE trial (18 months) in schizophrenia patients, diabetes incidence was 12% on quetiapine versus 8% on perphenazine.
Not supported by the provided label excerpt.
Meta-analyses of 15 RCTs report an odds ratio of 1.5–2.0 for diabetes with atypical antipsychotics such as Seroquel.
Not supported by the provided label excerpt.
Post-marketing surveillance confirms rare but severe cases of hyperglycemia-related complications with Seroquel, including fatalities from ketoacidosis.
Not supported by the provided label excerpt.
Switching to aripiprazole or ziprasidone is associated with minimal metabolic impact.
Not supported by the provided label excerpt.
The diabetes odds ratio for alternatives such as aripiprazole or ziprasidone is reported as approximately 1.0–1.2.
Not supported by the provided label excerpt.
Clozapine poses similar or higher risks of diabetes compared with Seroquel.
Not supported by the provided label excerpt.
Olanzapine poses similar or higher risks of diabetes compared with Seroquel.
Not supported by the provided label excerpt.
Contradictions
Important Omissions
The supplied claims do not address the boxed-warning topics that are actually present in the provided prescribing information excerpt (increased mortality in elderly patients with dementia-related psychosis; suicidal thoughts/behaviors in adolescents/young adults).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
Multiple detailed diabetes/hyperglycemia safety claims (including quantitative incidence and mechanistic/clinical thresholds) are unsupported by the provided label excerpt. This creates risk of misinformation relative to the supplied FDA-approved prescribing information.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about hyperglycemia/diabetes risk and related monitoring/quantitative rates, but the provided FDA label excerpt contains only dementia-related mortality and suicidality boxed-warning/precaution content and does not support these metabolic claims.
Suggested Improvement
Limit statements strictly to what is in the provided prescribing information excerpt (Sections 5.1/5.2/5.3 and related boxed-warning counseling in Section 17). Remove or re-evaluate all hyperglycemia/diabetes, monitoring-threshold, trial/meta-analysis, receptor/mechanism, and comparative metabolic-risk claims unless supported by additional FDA label sections not included in the prompt.